Dinda Ramadhina, Vallery Violila, Fatma Lestari, Debby Paramitasari, Abdul Kadir, Amin Subandrio, Hendy Risdianto Wijaya


COVID-19 Vaccine, as an antigenic material which produces body immunity is one the possible solutions to end COVID-19. The Indonesian government has started a vaccination program since January 2021 with two vaccine varieties, namely Astrazeneca and Sinovac. The objective of this paper is to give an illustration and provide statistics regarding the Covid-19 Vaccination process in Indonesia and its challenges. The research method that we used is literature study from the Indonesian vaccination process data from planning, execution, and post-vaccine results based on the Indonesian Ministry of Health’s Director General on Prevention and Disease control Number HK.02.02/4/ 1 /2021; various papers regarding Sinovac and Astrazeneca; Websites such as Indonesian Ministry of Health’s Website, KPCPEN (National Committee on Covid-19 Prevention and Economic Recovery) Website, non-government news sites, and journals regarding Indonesian vaccination process. Data were then analyzed using content analysis. This paper shows some challenges during the vaccination process including lack of vaccine acceptance by the public due to lack of awareness and understanding on the vaccination process; lack of knowledge regarding the vaccine quality, and lack of understanding regarding the vaccination process. Some other challenges also the curiosity on the possibility of post COVID-19 incidents known as Kejadian Ikutan Pasca Vaksinasi (KIPI), COVID-19 confirmed cases after COVID-19 vaccination and cases where people die after vaccination due to comorbid diseases. Regardless of challenges that are present, the government has taken the correct steps regarding the planning and execution of the vaccination process. Some challenges, gaps and opportunities will be described and provides recommendation for future corrective actions.

Full Text:



  • There are currently no refbacks.